Construction plan of mRNA therapeutics and vaccine production facility has been adopted for “Biopharmaceutical Production Base Development Project for Strengthening the Vaccine Production System” by the Ministry of Economy, Trade and Industry
ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”) announced today that the construction plan of ARCALIS mRNA therapeutics and vaccine manufacturing facility had been adopted for the subsidy of “Project for Establishment of Biopharmaceutical Manufacturing Facilities to Strengthen the Vaccine Production System *1( “Project”),” publicly solicited by the Ministry of Economy, Trade and Industry. This construction plan is a joint project with Meiji Seika Pharma Inc. (Head Office: Chuo-ku, Tokyo; President: Daikichiro Kobayashi; “Meiji Seika Pharma”).
Under this adoption, ARCALIS constructs an Formulation and Fill-finished product plant next to Drug Substance plant＊2 (Minamisoma-city Fukushima) to enable ARCALIS to accelerate the establishment of an integrated manufacturing value chain for mRNA drug substance and vaccine production.
＊1 About “Project for Establishment of Biopharmaceutical Manufacturing Facilities to Strengthen the Vaccine Production System”
In order to prepare for infectious diseases that may become a threat in the future, this project supports the introduction of facilities to establish bases with dual-use facilities that can manufacture biopharmaceuticals according to the needs of companies in normal times and switch to vaccine production in the event of an infectious disease pandemic, as well as equipment installation support for the introduction of facilities for the development of bases equipped with vaccine formulation and filling facilities and part material production facilities for the pharmaceutical products.
＊2 About ARCALIS Minamisoma Plant
As a CDMO for mRNA therapeutics and vaccines, ARCALIS has started construction of an API manufacturing plant in Minamisoma City. From July 2023, we are working to establish a manufacturing system for the API for Replicon Vaccine (next-generation mRNA vaccine) developed by one of our founding shareholders, Arcturus Therapeutics, Inc. The company has already started construction of an API manufacturing plant in Minamisoma City, Fukushima Prefecture, Japan.